Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single and multiple ascending dose study of SAR443122 in healthy adults
NL-OMON48479Phase 1Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eclitasertib in autoimmune disease and rheumatoid arthritis (RA) (11 arms), sponsored by Sanofi. Primary endpoints: Safety and tolerability after single ascending oral doses, Relative bioavailability and 2 more. Started Jun 2019; status: active, not recruiting.
02
Drugs
eclitasertib
03
Conditions
autoimmune diseaserheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON48479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48479.